Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice by Henry, Brian D et al.
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The global burden of bacterial disease remains high and is set against 
a backdrop of increasing antimicrobial resistance1,2. There is a press-
ing need for new therapeutic strategies that are less likely to lead to 
drug resistance3.
Many bacterial pathogens secrete protein toxins that kill or damage 
host cells by forming pores in the host cell membrane (pore-forming 
toxins) or by degrading plasmalemmal lipids (lipases). Membrane-
damaging toxins such as cholesterol-dependent cytolysins (CDCs: 
pneumolysin, streptolysin O, tetanolysin), α-hemolysin or bacterial 
phospholipase C have a crucial role in the establishment and progres-
sion of infectious diseases4–7.
The CDC family comprises more than 20 members from different 
Gram-positive bacterial genera including Clostridium, Streptococcus, 
Listeria and Bacillus8. Pneumolysin, secreted by S. pneumoniae, and 
streptolysin O, secreted by Streptococcus pyogenes, insert directly in 
the plasmalemmal lipid bilayer of target cells and form oligomeric 
pores that are large enough to allow the leakage of intracellular 
proteins8–10.
α-Hemolysin, which is secreted by Gram-positive S. aureus, 
forms small pores that primarily affect the intracellular ion balance. 
Its oligomers insert directly into the lipid bilayer: a basic and aro-
matic amino-acid-rich crevice between the rim domain and the stem 
domain forms a binding site for phospholipid headgroups9,11. Gram-
negative pathogens also secrete a variety of repeats-in-toxins that pos-
sess pore-forming or lipase activity12.
The lipid bilayer of the plasmalemma is mainly composed of gly-
cerophospholipids, sphingolipids and cholesterol. Cholesterol and 
sphingomyelin are logical choices as target molecules for bacterial 
toxins as they confer specificity for animal cells as opposed to bacte-
rial cell membranes8,9,13. It appears that increased levels of cholesterol 
within distinct membrane microdomains, but not the mere presence 
of individual cholesterol molecules within the plasma membrane, 
are important for pore-forming toxin activity8–10. Such lipid micro-
domains assemble within the plasmalemma of eukaryotic cells as 
a result of the interactions of sphingolipids with one another and 
with cholesterol, followed by the accumulation of these lipids within 
membrane rafts14–17. Rafts are characterized by a tight packing of 
saturated acyl chains within the liquid ordered phase, whereas gly-
cerophospholipids, with preferentially unsaturated acyl chains, reside 
in a more fluid liquid-disordered phase14–16. Raft microdomains 
in vivo are unstable structures less than 40 nm in diameter14,15.
Unlike unstable in vivo rafts, stable, liquid-ordered, lipid micro-
domains can be artificially created in liposomes consisting of cho-
lesterol and sphingomyelin18. Here, we explore whether liposomes 
comprising higher than in vivo relative concentrations of selected 
lipids can be used as decoy targets to sequester bacterial membrane-
damaging toxins. Using individual, purified bacterial toxins we 
establish that liposomes composed of sphingomyelin in combina-
tion with artificially high concentration of cholesterol (cholesterol:
sphingomyelin liposomes; 66 mol/% cholesterol) efficiently bind 
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CDCs, phospholipase C and α-hemolysin. Furthermore, a mixture 
of cholesterol:sphingomyelin liposomes (66 mol/% cholesterol) with 
sphingomyelin liposomes (sphingomyelin-only liposomes) efficiently 
sequester the whole palette of toxins released by a variety of staphylo-
coccal and streptococcal pathogens. The same mixture of liposomes 
is successfully used to treat fatal invasive staphylococcal and strep-
tococcal diseases in mouse models, either alone or in combination 
with antibiotic therapy.
RESULTS
Sequestration of purified bacterial toxins
We initially assessed whether an artificially high concentration of a 
particular target lipid increases the affinity of liposomes for membrane- 
damaging toxins and thereby allows a preferential binding 
of the toxin to liposomes compared to mammalian cells. As CDCs 
bind directly to plasmalemmal cholesterol, and this interaction 
is augmented within cholesterol- and sphingomyelin-rich lipid 
microdomains, we made liposomes that were saturated with cholesterol 
(the maximal concentration of cholesterol that can be accommodated 
within a lipid bilayer is 66 mol/% (ref. 19)) and contained sphin-
gomyelin as a bilayer-forming lipid (cholesterol:sphingomyelin; 
66 mol/% cholesterol). When added to the cell-liposome mixture, 
pneumolysin exclusively targeted the cholesterol:sphingomyelin 
liposomes, whereas the cells remained toxin-free (Fig. 1a; full-sized 
blot is shown in Supplementary Fig. 1).
We next investigated whether cholesterol:sphingomyelin lipo-
somes were able to protect human epithelial cells, endothelial cells 
and cells of the innate immune system, which are the major effector 
cells responsible for fending off a pathogen attack, from a number 
of purified bacterial toxins. Additionally, cholesterol:sphingomyelin 
liposomes (66 mol/% cholesterol) were compared with liposomes of 
other lipid compositions in order to gain insights into basic princi-
ples that govern liposome-toxin interaction. The amounts of puri-
fied toxins required for complete inhibition of proliferation of human 
monocyte THP-1 cells were established (Supplementary Fig. 2) and 
used in all subsequent experiments.
Cholesterol:sphingomyelin liposomes (cholesterol = 66 mol/%) 
completely protected THP-1 cells from CDCs (streptolysin O, 
tetanolysin, pneumolysin), α-hemolysin and phospholipase C (Fig. 1b 
and Supplementary Fig. 3a). Liposomes that contained no choles-
terol were ineffective against pneumolysin and α-hemolysin; limited 
protection against phospholipase C was observed for sphingomyelin- 
only but not for phosphatidylcholine-only liposomes (Fig. 1c). 
The amounts of the cholesterol:sphingomyelin liposomes that were 
required for the neutralization of the cytotoxic activity of pneumo-
lysin (Supplementary Fig. 3b) were comparable to those that were 
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Figure 1 Liposomes composed of cholesterol and sphingomyelin protect monocytes from cholesterol-dependent cytolysins,  
α-hemolysin (HML) and phospholipase C (PLC). (a) Pneumolysin (PLY) was added to THP-1 cells without liposomes (+,–);  
to a mixture of THP-1 cells with cholesterol:sphingomyelin (Ch:Sm) liposomes (+,+); to Ch:Sm liposomes without cells (–,+)  
or to buffer-only (–,–). The samples were centrifuged at low-speed (cell pellet), then at high-speed (liposome pellet).  
The resulting pellets and the high-speed supernatant were analyzed by western blotting for PLY content. In the absence of either  
cells or liposomes, PLY was recovered in the high-speed supernatant; in the absence of liposomes, PLY was bound by the cells  
and was recovered preferentially in the low-speed pellet; in the absence of cells, PLY was bound by the liposomes and was  
recovered in the high-speed pellet. In the cell-liposome mixture, PLY exclusively targeted the liposomes. (n = 6). Full-sized  
blot in Supplementary Figure 1. (b) Liposomes composed of Ch (66 mol/%) in combination with phosphatidylcholine (PC),  
Sm or phosphatidylserine (PS) protect THP-1 cells from PLY or PLC. Ch:Sm liposomes are most effective against HML (n = 9). (c) Liposomes without 
cholesterol do not protect THP-1 cells from PLY or HML. Sm-only, but not PC-only liposomes, give limited protection against PLC (n = 6). (d) Artificially 
high concentrations of cholesterol within Ch:Sm liposomes are required for protection against PLY, tetanolysin (TL) or HML. (n = 9). (e) Ch:Sm 
liposomes protect THP-1 cells from the combination of streptolysin O (SLO) (400 ng), TL (200 ng) and HML (1.2 µg) (n = 7). (f) A mixture of  
SLO + TL + HML was incubated with or without Ch:Sm liposomes, followed by centrifugation. The liposomal pellet was discarded; the supernatants  
were added to the cells. The liposome-free supernatants of the toxin-liposome mixture do not damage exposed cells. This is in contrast to toxin 
preparations that were centrifuged in the absence of liposomes. (n = 4). PC:Sm = (1:1 w/w). Error bars, mean ± s.e.m.
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required for the sequestration of the toxin, established in a direct 
binding experiment (Supplementary Fig. 3c).
Liposomes containing cholesterol at 20–30 mol/% concentration, 
which is similar to total cholesterol concentration occurring in vivo20–22, 
were unable to compete with cells for toxin binding; artificially high 
cholesterol concentrations above 50 mol/% were required for cholesterol: 
sphingomyelin liposomes to fully protect monocytes from lysis by 
pneumolysin, tetanolysin or α-hemolysin (Fig. 1d).
The relative ratio of cholesterol to phospholipid within lipid bilay-
ers rather than its total concentration defined the protective potential 
of cholesterol-containing liposomes: 3 µg (total cholesterol = 1.5 µg) 
of cholesterol:sphingomyelin liposomes with high contents of cho-
lesterol (66 mol/%) provided complete protection against 200 ng of 
tetanolysin (Supplementary Fig. 3b), whereas 17 µg (total cholesterol = 
3.4 µg) of cholesterol:sphingomyelin containing 33 mol/% of cho-
lesterol provided no protection (Fig. 1d).
Liposomal cholesterol was >1,000 times more effective in neutraliz-
ing streptolysin O than cholesterol that was present in vivo in the form 
of high-density lipoprotein (HDL); 0.2 µg of liposomal cholesterol was 
required for half-maximal neutralization of 400 ng of streptolysin O 
(Supplementary Fig. 3b), whereas >300 µg of HDL cholesterol was 
needed for the same degree of protection (Supplementary Fig. 3d).
Cholesterol:sphingomyelin liposomes exerted fully protective 
effects against the combined action of streptolysin O, tetanolysin and 
α-hemolysin (Fig. 1e). Sequestration of all three toxins by cholesterol:
sphingomyelin liposomes was confirmed in a direct binding experi-
ment (Fig. 1f).
Collectively, our results demonstrate that cholesterol:sphingomy-
elin liposomes (cholesterol = 66 mol/%) efficiently sequestered a vari-
ety of purified toxins belonging to different toxin classes with diverse 
modes of membrane-damaging action.
Epithelial and endothelial cells constitute physical barriers to path-
ogens. Human embryonic kidney epithelial cells (HEK 293) that were 
treated with pneumolysin or with phospholipase C lost their entire 
cytosol within 10 min of the toxin exposure (Fig. 2a–c). The loss of 
cytosol, that is, immediate cell lysis, was prevented when cholesterol:
sphingomyelin liposomes were added to the cells before the toxin 
exposure (Fig. 2a–c), whereas sphingomyelin-only liposomes were 
not protective (Fig. 2b).
Cholesterol:sphingomyelin liposomes (cholesterol = 66 mol/%) 
also protected human endothelial HUVEC cells from pneumolysin-
induced lysis (Fig. 2d) and prevented pneumolysin-induced release 
of CXCL8 (also known as IL-8) by these cells at sublytic pneumo-
lysin concentrations (Fig. 2e). Thus, liposomal toxin sequestration 
not only prevented endothelial cell damage but also precluded their 
toxin-induced inflammatory activation. The latter might be of utmost 
importance in vivo, because uncontrolled, overwhelming inflamma-
tory responses during bacterial infection can lead to extensive tissue 
damage in the host23. Pneumolysin concentrations used in our study 
(60–800 ng/ml) were comparable to those occurring during invasive 
disease in vivo24–26.
Sequestration of toxins secreted by human pathogens
We next checked whether artificial liposomes could sequester the full 
panoply of toxins secreted by clinically relevant human pathogens.
Cholesterol:sphingomyelin liposomes completely protected THP-1 
cells from the effect of toxins secreted by all of the S. pyogenes 
strains tested (Fig. 3a,b). The amount of cholesterol:sphingomyelin 
liposomes that was required to achieve complete protection against 
S. pyogenes DSM 11728 (Fig. 3b) was comparable to the amounts of 
liposomes that were fully protective against purified streptolysin O 
(Supplementary Fig. 3b), suggesting that this toxin is the single 
cytotoxic agent that is secreted by this pathogen.
In contrast, cholesterol-containing liposomes (either cholesterol:
sphingomyelin or cholesterol:phosphatidylcholine) provided only 
limited protection against toxins secreted by a methicillin-resistant 
strain of S. aureus (MRSA 2040) (Fig. 3c). However, a combination 
of cholesterol-containing liposomes (cholesterol = 66 mol/%) with 
cholesterol-free, sphingomyelin-only liposomes yielded full protec-
tion against this pathogen (Fig. 3d,e). Figure 3d shows the results of 
an experiment in which the survival of THP-1 cells was assessed 
in the presence of an invariable amount (600 µg) of cholesterol: 
phosphatidylcholine liposomes and increasing amounts of either 
phosphatidylcholine-only or sphingomyelin-only liposomes. At these 
experimental conditions, the relative survival at the “0 µg” point (Fig. 3d; 
black arrow) corresponds to that of the “600 µg” point (Fig. 3c, 
black arrow). Used alone, 600 µg of cholesterol-containing liposomes 
provided only limited protection against toxins secreted by MRSA 2040 
(Fig. 3c,d; black arrows). Combining 600 µg of cholesterol-containing 
liposomes with up to 225 µg of phosphatidylcholine-only liposomes 
provided no additional protection (Fig. 3d). However, the addition of as 
little as 75 µg of sphingomyelin-only liposomes rendered the liposomal 
mixture fully protective against toxins secreted by MRSA 2040 (Fig. 3d). 
In a reciprocal experiment, the survival of THP-1 cells was assessed 
a PLY
0
T
im
e 
af
te
r 
to
xi
n 
(s
)
PLY + liposomes
60
0
c
T
im
e 
af
te
r 
to
xi
n 
(s
)
PLC PLC + liposomes
0
50
0
d
T
im
e 
af
te
r 
to
xi
n 
(s
)
0
50
0
Liposomes (µg)
PLY (200 ng)
0 0.4 0.8 1.6
b PLY
R
el
at
iv
e 
su
rv
iv
al 1.0
0.5
0
0 1 2
Liposomes (µg)
3
Sm
Ch:Sm
e
C
X
C
L8
 (
pg
/m
l)
800
600
400
200
0
PLY
Liposomes
PLY (15 ng)
*** ***
– –
–– +
+ +
+
Figure 2 Cholesterol:sphingomyelin (Ch:Sm) liposomes protect epithelial and endothelial cells from lysis by pneumolysin 
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in the presence of invariable, saturating amounts of sphingomyelin- 
only liposomes (300 µg) and increasing amounts of cholesterol: 
phosphatidylcholine liposomes (Fig. 3e). At such experimental con-
ditions the relative survival at the “0 µg” point (Fig. 3e; blue arrow) 
corresponds to that of the “300 µg” point (Fig. 3c, blue arrow). 
Used alone, 300 µg of sphingomyelin-only liposomes provided no pro-
tection against toxins secreted by MRSA 2040 (Fig. 3c,e, blue arrows). 
Combining 300 µg of sphingomyelin-only liposomes with up to 
400 µg of cholesterol-containing liposomes provided no additional 
protection (Fig. 3e), but increasing the amount of cholesterol- 
containing liposomes to 600 µg rendered the liposomal mixture fully 
protective against toxins secreted by MRSA 2040 (Fig. 3e).
Taken together, these results suggest that MRSA 2040 secretes at 
least two toxins. One toxin is neutralized by sphingomyelin-only lipo-
somes (complete neutralization at ≤75 µg), whereas the second toxin 
is neutralized by 400–600 µg of cholesterol-containing liposomes.
Liposomal treatment was also effective against a strain of S. aureus 
that was isolated from a septic patient (septic S. aureus strain). In con-
trast to the MRSA 2040 strain, the cytolytic toxins secreted by the sep-
tic S. aureus strain were partially sequestered by sphingomyelin-only 
liposomes but not by the cholesterol-containing liposomes (Fig. 3f), 
suggesting that the relative contribution of sphingomyelin-binding 
toxin(s) to the total cytotoxic activity of this pathogen was higher than 
that of the cholesterol-binding toxin(s). The toxin-sequestering activ-
ity of sphingomyelin-containing liposomes was drastically decreased 
when sphingomyelin was replaced by the same-headgroup glycerolipid, 
phosphatidylcholine (Fig. 3g). As in the MRSA 2040 strain, the combi-
nation of sphingomyelin-only liposomes with cholesterol-containing 
liposomes (66 mol/%) was required for full protection against the 
septic S. aureus strain (Fig. 3h).
The mixture of cholesterol:sphingomyelin liposomes (cholesterol = 
66 mol/%) and sphingomyelin-only liposomes was also protective 
against clinically isolated MRSA strains (Fig. 3i).
For S. pneumoniae, limited protection achieved with low amounts 
of cholesterol:sphingomyelin liposomes alone (Fig. 3j) can be attrib-
uted to sequestration of pneumolysin (Supplementary Fig. 3b). The 
mixture of cholesterol-containing and sphingomyelin-only liposomes 
was fully protective against this pathogen (Fig. 3k).
Sequestration of bacterial toxins in vivo
We next investigated whether the mixture of cholesterol-containing 
(cholesterol = 66 mol/%) and cholesterol-free, sphingomyelin-
 containing liposomes protects mice from fatal staphylococcal and 
pneumococcal disease.
Initially, we evaluated biotoxicity and biodistribution of the lipo-
somes in healthy mice. The doses of liposomes that were routinely 
used in our study (100–150 mg/kg) are known to be nontoxic when 
liposomes are used as carriers for the intravenous delivery of anti-
biotics in rats (400 mg/kg)27. This is consistent with our findings 
that the hearts, kidneys, livers, lungs and spleens of mice that were 
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treated with 100 mg/kg of the liposomal mixture showed no obvi-
ous macroscopic or microscopic changes (Supplementary Fig. 4). 
Biodistribution was assessed by mass spectrometry in mice that were 
injected with liposomes that contained 6% of deuterated sphingomy-
elin. The half-maximal decline in the level of circulating liposomes 
occurred at 4 h, whereas ~20% of the liposomes were still circulat-
ing at 24 h after injection (Supplementary Fig. 5). The highest per 
organ accumulation of deuterated sphingomyelin was observed in the 
liver, followed by the spleen and the intestine. The highest specific 
(per mg of protein) retention of liposomes was detected in spleens 
6–24 h after injection (Supplementary Fig. 5), which is indicative of 
their elimination by splenic macrophages.
We next tested the efficacy of liposomes as treatment for severe 
bacterial disease in mice. In an invasive pneumococcal pneumonia 
model, mice were infected intranasally with S. pneumoniae sero-
type 2 (strain D39). Liposomes provided protection against invasive 
pneumonia (Fig. 4a). In accord, reductions of bacterial load were 
observed in the blood and lungs of mice treated with the liposomal 
mixture (Fig. 4b). Importantly, the levels of TNF-α, a signature pro-
inflammatory cytokine associated with pneumococcal infection, 
were considerably reduced in the liposome-treated mice (Fig. 4c). 
Histological analysis of lungs obtained 24 h after infection from 
mice infected intranasally with S. pneumoniae showed prominent 
peribronchiolar and perivascular inflammatory cuffs (Supplementary 
Fig. 6). In lungs of the liposome-treated mice edematous changes 
in the peribronchiolar and perivascular connective tissue were 
marked, but infiltration by leukocytes was reduced (Supplementary 
Fig. 6). No obvious microscopic changes were observed in the lungs 
of healthy mice that were treated intranasally with the liposomal 
mixture (Supplementary Fig. 6).
In a fatal pneumococcal sepsis model, mice were injected intra-
venously with a lethal dose of S. pneumoniae D39. Mice that were 
not treated with liposomes died within 33 h of bacterial challenge 
(Fig. 4d). A single injection of the liposomal mixture was protective 
when given at 6 h or 10 h after infection, whereas injection at 16 h 
was ineffective (Fig. 4d). A considerable reduction of the bacterial load 
was observed in the blood of mice that had been injected with a single 
dose of the liposomes at 6 h or at 10 h after infection (Fig. 4e). As we 
observed in the lungs of mice in the invasive pneumococcal pneumonia 
model, blood levels of TNF-α were also substantially reduced in the 
pneumococcal sepsis model in mice that were injected with the lipo-
somal mixture 6 h after intravenous infection (Fig. 4f). Furthermore, a 
single injection of liposomes attenuated the bacteremia-induced reduc-
tion of blood B-cells and reduced the pro-inflammatory recruitment 
of blood polymorphonuclear leukocytes, a major contributing factor 
to uncontrolled inflammation, whereas the levels of T-cells were not 
affected either by bacteremia or by the liposomal treatment (Fig. 4g). 
Injection of the liposomal mixture in healthy mice did not influence 
levels of either TNF-α or that of blood leukocytes (Fig. 4f,g).
Because the levels of liposomes in blood decreased by 50% 4 h after injec-
tion (Supplementary Fig. 5a), we injected mice with liposomes twice with 
a 4 h interval to maintain a high level of circulating liposomes. No control 
or sphingomyelin-only mice survived beyond 32 h (Fig. 4h). However, 
6 out of 8 mice that received the cholesterol:sphingomyelin plus sphingo-
myelin-only liposomal mixture and 3 out of 8 mice that received choles-
terol:sphingomyelin liposomes survived. The cholesterol:sphingomyelin 
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Figure 4 A mixture of cholesterol:sphingomyelin (Ch:Sm) + Sm-only liposomes confers survival in mice infected  
with S. pneumoniae. (a) Pneumonic mice, infected intranasally with S. pneumoniae D39, were given an intranasal  
administration of 100 mg/kg of a 1:1:1:1 mixture of Ch:Sm (66 mol/% cholesterol) + Ch:PC (66 mol/% Ch) + Sm-only +  
Sm:PC (75 mol/% Sm) liposomes or saline 30 min after infection and evaluated for survival (n = 10). Both types of  
Ch-containing liposomes and Sm-containing liposomes were equally protective against corresponding toxins in vitro.  
(b,c) Pneumonic mice, infected intranasally with S. pneumoniae D39, were given an intranasal administration of  
100 mg/kg of a 1:1 mixture of Ch:Sm + Sm-only liposomes or saline 30 min after infection and evaluated for  
bacteremia in blood (n = 10) or in lungs (n = 4) (b); and for release of TNF-α in lungs (n = 4) (c). (d–g) Bacteremic  
mice, infected intravenously with S. pneumoniae D39, were given an intravenous administration of 100 mg/kg  
liposomes 6 h or 10 h or 16 h after infection and evaluated for survival (n = 10) (d); for bacteremia in blood (n = 10) (e); for release of TNF-α in 
blood (n = 4) (f); and for changes in blood leukocytes (n = 4) (g). (h,i) Bacteremic mice, infected intravenously with S. pneumoniae D39, were given 
intravenous administrations of 150 mg/kg/injection of Ch:Sm + Sm-only or Ch:Sm or Sm-only liposomes or saline 8 and 12 h after infection and 
evaluated for survival (h; n = 8) and bacteremia in blood (i; n = 8). Error bars, mean ± s.e.m. ***P < 0.001; **P < 0.01; *P < 0.05.
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plus sphingomyelin-only group had the lowest average colony-forming 
units (CFU) counts after 24 h of bacteremia (Fig. 4i).
In a staphylococcal sepsis model, mice were injected intravenously 
with a lethal dose of the septic S. aureus strain. None of the control 
mice survived beyond day 3 (Fig. 5a). Treatment with ≥100 mg/kg 
per injection of the liposomal mixture resulted in complete recovery 
of the infected mice (Fig. 5a), whereas lower doses provided par-
tial protection. The liposomal treatment (100 mg/kg per injection) 
prevented development of pulmonary edema in the infected mice, a 
typical feature of severe S. aureus sepsis (Fig. 5b). A single injection 
of the liposomes (100 mg/kg) was equally protective at 2 h, 6 h or 10 h 
after infection (4 mice for each time point; all survived), whereas an 
injection 16 h after infection was ineffective (4 mice; death after 36, 
40, 48 and 52 h).
Mechanism of protection by liposomes
Liposomal treatment considerably reduced TNF-α levels both in the 
invasive pneumococcal pneumonia model and in the pneumococcal 
sepsis model (Fig. 4c,f). Although TNF-α aids in the bacterial clear-
ance process, excessive production of this cytokine during infection 
leads to uncontrolled inflammation (cytokine storm), and increased 
mortality. Liposomes that contain negatively charged phosphatidyl-
serine have been shown to inhibit TNF-α-release from lipopolysac-
charide (LPS)-treated cells28. The liposomes used in this study did 
not contain phosphatidylserine, and their protective action was not 
due to an inhibition of LPS-induced TNF-α overproduction. Mice 
that were injected intravenously with 150 mg/kg of the cholesterol:
sphingomyelin plus sphingomyelin-only liposomal mixture 45 min 
after administration of LPS from Escherichia coli or Pseudomonas 
aeruginosa (n = 2 for each group) and control mice that received an 
injection of normal saline 45 min after LPS administration (n = 3) 
died within 36 h of LPS administration.
The reduced TNF-α levels seen in liposome-treated mice may be 
the result of decreased bacterial numbers and/or reduced toxin-
 mediated damage and cellular activation. Liposomal treatment 
considerably decreased bacterial loads in infected animals (Fig. 4b,e). 
Yet, the liposomes themselves are not bactericidal: the minimal 
bactericidal concentration was >16 mg/ml for S. aureus and S. pneumoniae. 
In addition, we observed no evidence that the liposomes either 
modified bacterial killing by mouse blood (Fig. 5c) or activated 
neutrophils to release nitric oxide (Fig. 5d) and reactive oxygen 
species (Fig. 5e).
Our in vitro data suggest that the major decrease in bacterial load 
in infected animals after liposomal treatment is due to the protection 
of host immune cells from lysis by the bacterial toxins. Accordingly, 
in the staphylococcal sepsis model, injection of the cholesterol: 
sphingomyelin plus sphingomyelin-only liposomal mixture protected 
mouse leukocytes from killing by S. aureus in vivo (Fig. 5f).
To provide further evidence that the liposomes prevented fatal 
infection by sequestering bacterial toxins, mice were injected with 
bacteria-free culture supernatants obtained from the septic S. aureus 
strain (Fig. 5g). All mice that received bacterial supernatants, 
 incubated with PBS, died within 34 h after the injection, whereas all 
mice that received liposome-treated supernatants survived. Liposomal 
pre-treatment prevented the development of lung edema in mice that 
were injected with bacterial supernatants (Fig. 5h).
Collectively these experiments demonstrate that liposomal protec-
tion in vivo was due neither to direct bactericidal activity nor to a 
direct activation of host defenses by the liposomes. Nor did it require 
direct liposome-host, bacteria-host or bacteria-liposome interactions; 
the sequestration of secreted bacterial toxins by the mixture of 
cholesterol:sphingomyelin plus sphingomyelin-only liposomes was 
sufficient to protect host cells from lysis and uncontrolled inflamma-
tory hyperactivation and to prevent death of infected animals.
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Figure 5 A mixture of cholesterol:sphingomyelin (Ch:Sm) + Sm-only  
liposomes confer survival in mice infected with S. aureus. (a) Mice were  
infected intravenously (i.v.) with the septic S. aureus strain and treated  
i.v. with 12.5–400 mg/kg of a 1:1 mixture of Ch:Sm + Sm-only liposomes.  
The liposomes were administered 2 h after the infection and the liposomal  
treatment was repeated 6 and 24 h after infection. Mice that were not  
treated with liposomes received an equal volume of 0.9% normal saline.  
Survival was measured (n = 10). (b) Mice were infected i.v. with the septic  
S. aureus strain and treated intravenously with 100 mg/kg of a 1:1 mixture  
of Ch:Sm + Sm-only liposomes, administered 2 and 6 h after infection.  
Lung edema was evaluated by comparing wet/dry weight of the lungs  
(n = 4) and by monitoring the intrapulmonal leakage of Evans Blue (n = 4). (c) Blood samples obtained from healthy mice were incubated with S. aureus 
in the presence or absence of Ch:Sm + Sm-only liposomes. After the incubation, aliquots were plated on LB plates, grown overnight and the CFU were 
counted (n = 4). Corresponding data (indicated by arrows) are shown on a magnified scale to highlight that liposomes had no effect on bacterial killing 
by mouse blood. TSB, tryptic soy broth. (d,e) Ch:Sm + Sm-only liposomes had no effect on the capability of purified mouse neutrophils to release nitric 
oxide (NO) (n = 4) (d) or reactive oxygen species (ROS) (n = 4) (e) upon infection with S. aureus. NO was determined in the presence or absence of L-
NAME (i-NOS inhibitor). DAF, 4-amino-5-methylamino-2′,7′-difluorofluorescein; DCF, 2′,7′dichlorodihydrofluorescein diacetate acetyl ester. (f) Mice 
were infected i.v. with the septic S. aureus strain and were treated 2 and 6 h after infection i.v. with Ch:Sm + Sm-only liposomes or PBS. Control mice 
received PBS only. The number of leukocytes was measured by FACS (n = 4). (g,h) S. aureus culture supernatant was incubated with Ch:Sm + Sm-only 
liposomes or with an equal volume of PBS. Liposomes were removed by centrifugation and supernatants were injected i.v. in mice. Survival (n = 10) (g) 
and lung edema (n = 4) (h) were evaluated. Error bars, mean ± s.e.m. ***P < 0.001; **P < 0.01; *P < 0.05.
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Adjunct therapy with liposomes
Antibiotics are the mainstay of treatment against bacterial infection 
but massive release of bacterial toxins owing to bacterial lysis during 
antibiotic therapy might result in more severe pathology than the infec-
tion itself23,29. Therefore, we investigated whether the combination 
of liposomes with antibiotic treatment could be beneficial in mouse 
S. aureus and S. pneumoniae bacteremia models.
Neither the very low doses of 12.5 mg/kg/injection of the lipo-
somal mixture nor 100 mg/kg/injection vancomycin were sufficient 
to protect the mice from the lethal effects of a systemic S. aureus 
infection, whereas the combination of both provided complete protec-
tion (Fig. 6a). A combination of liposomal toxin-sequestration and 
antibiotic treatment was also most effective against fatal sepsis caused 
by S. pneumoniae (Fig. 6b). In the course of antibiotic-liposome com-
bination therapy, pneumococcal loads in blood 24 h after infection 
were considerably reduced as compared to antibiotic alone and the 
pain score (i.e., signs of disease) of mice that were infected with 
S. pneumoniae were completely eradicated (Fig. 6c,d).
DISCUSSION
Survival of patients with bacteremia and sepsis is dependent 
on timely antimicrobial treatment. However, with an increasing 
number of antibiotic-resistant pathogens, the selection of empiric 
antimicrobial treatment has become difficult30.
We have engineered artificial liposomal decoys that bind bacterial 
toxins and used them to treat fatal infections in mice. We show that 
the binding of toxins depends on the presence of certain lipids and/or 
liquid-ordered lipid microdomains within the liposomes, consistent 
with the makeup of host cell plasmalemma. Artificial liposomes 
efficiently sequestered multiple purified toxins belonging to different 
toxin classes with diverse modes of membrane-damaging action and 
protected human epithelial and endothelial cells as well as cells of 
the innate immune system from the toxin-induced lysis. Protection 
against CDCs by cholesterol-containing liposomes is consistent with 
the notion that these toxins bind directly to cholesterol9. However, as 
the relative ratio of cholesterol to phospholipid within lipid bilayers 
rather than its total concentration defined the protective potential of 
cholesterol-containing liposomes, it is conceivable that cholesterol-
rich raft microdomains are preferentially targeted by these toxins 
in vivo. In addition, the preferential protection against α-hemolysin 
by cholesterol:sphingomyelin liposomes is consistent with the notion 
that α-hemolysin binds to sphingomyelin, which is clustered within 
raft microdomains11.
Liposomes sequestered the full panoply of toxins secreted by indi-
vidual strains of staphylococcal and streptococcal pathogens. Whereas 
a single toxin was responsible for the cytolytic activity of S. pyogenes, 
multiple toxins with different modes of plasma membrane binding 
were secreted by S. aureus. At least one staphylococcal toxin was 
sequestered by cholesterol-containing liposomes, whereas another 
toxin(s) bound to cholesterol-free, sphingomyelin-containing lipo-
somes. The similarities between liposomal neutralization of bacterial 
culture supernatants and the neutralization of purified bacterial tox-
ins allow, with a high degree of confidence, matching of the cytotoxic 
activity of S. pneumoniae and S. pyogenes to that of pneumolysin and 
streptolysin O, respectively. Phospholipase C or α-hemolysin might 
be responsible for the cytotoxic activity of staphylococci, although yet 
unidentified toxin(s) that bind to cholesterol-containing liposomes 
might also contribute to the cytotoxic activity of this pathogen. The 
nature of sphingomyelin-binding toxin(s) also requires definition. 
Although establishing the exact nature of cytotoxic agents that are 
targeted by cholesterol:sphingomyelin and sphingomyelin-only lipo-
somes requires further investigation, this caveat will not compromise 
the applicability of toxin-sequestration as a therapeutic approach, 
because, at least during the onset of a therapeutic intervention, the 
exact nature of the bacterial pathogens and their individual toxins 
will be unknown. Most importantly, the mixture of cholesterol:
sphingomyelin and sphingomyelin-only liposomes sequestered 
toxins that were secreted by all of the staphylococcal and strepto-
coccal strains tested so far, including clinical isolates and antibiotic- 
resistant pathogens.
We show that upon binding of exotoxins by artificial liposomes, 
bacteria were efficiently cleared by the host’s immune system in the 
mouse bacteremia models. Likewise, the mucosal, intranasal applica-
tion of liposomes protected mice from invasive pneumococcal pneu-
monia, significantly reducing pneumococcal loads. Although local 
protection of the host epithelia may prevent bacterial invasion, bind-
ing of membrane-damaging toxins in the bloodstream may facilitate 
the resolution of severe infection and bacteremia by preventing the 
death of immune cells. Liposome-mediated prevention of uncon-
trolled release of pro-inflammatory mediators might also be crucial 
for host survival and may contribute to preventing the development 
of life-threatening cytokine storm and septic shock. Furthermore, 
removal of toxins at the time of antibiotic therapy is of paramount 
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Figure 6 A combination of toxin-sequestration with antibiotic treatment to 
treat fatal S. aureus and S. pneumoniae infections. (a) Mice were infected 
i.v. with the septic S. aureus strain and randomly separated into four 
groups. Mice of the first group received injections of PBS as control.  
All 12 mice of this group died within 52 h of infection. Mice of the  
second group were treated i.v. with low doses of Ch:Sm + Sm-only 
liposomes, which were administered 2, 6 and 24 h after infection  
(total dose = 37.5 mg/kg). As the liposome dose is too low to provide 
complete protection, only 5 out of 12 mice survived the infection. Mice  
of the third group were treated i.v. with 100 mg/kg of vancomycin at  
1 and 9 h after infection. Only 4 out of 12 mice survived the infection if 
treated with vancomycin alone. Mice of the fourth group were treated i.v. 
with Ch:Sm + Sm-only liposomes and vancomycin administered as above. 
All 12 mice survived the infection. (b–d) Mice were infected i.v. with  
S. pneumoniae D39 and randomly separated into three groups. Mice of 
the first group received injections of PBS as a control. All ten mice of this 
group died within 48 h of infection (b). Mice of the second group were 
treated intravenously with 25 mg/kg of penicillin at 10 and 24 h after 
infection. Only 4 out of 10 mice survived in this group (b). Mice of the 
third group were treated intravenously with 100 mg/kg Ch:Sm + Sm-only 
liposomes and with 25 mg/kg of penicillin at 10 and 24 h post-infection.  
8 out of 10 mice survived the infection (b). The mice were further evaluated 
for bacteremia 24 h after infection (n = 10) (c) and for visible disease signs 
(n = 10) (d). Error bars, mean ± s.e.m. ***P < 0.001; *P < 0.05.
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importance, as the bacteriolytic nature of antibiotics can lead to acute 
release of bacterial toxins causing organ-specific defects.
We show that liposomal therapy is effective against Gram-positive 
pathogens. Two Gram-negative pathogens, E. coli and P. aeruginosa, 
were tested in our pilot study. However, these pathogens were not 
cytotoxic for THP-1 cells in our in vitro screening experiments. 
Therefore, tailoring of liposomal formulations, which is critical for 
in vivo testing, could not be carried out. We are currently testing alter-
native approaches for establishing liposomal formulations that can be 
used to sequester toxins secreted by Gram-negative pathogens.
Liposomes are currently used as carriers for drug delivery and 
are nontoxic for humans31. All components of our liposomal for-
mulations are naturally occurring lipids that are present in the outer 
leaflet of the plasmalemmal lipid bilayer, that is, they are exposed to 
the systemic circulation in vivo and thus are nonimmunogenic and 
biologically neutral. Because the liposomes are not bactericidal, it is 
unlikely that they will exert evolutionary pressure that would select 
for the emergence of drug-resistant bacteria32.
Our data provide a compelling argument for pursuing liposome-based, 
toxin-sequestrating therapy for use as a treatment for life-threatening 
bacterial infections. Liposomes could be used for the treatment of 
antibiotic-resistant bacterial pathogens, because they neutralize the 
bacterial toxins and allow time for the host immune system to eliminate 
the bacteria. The neutralization of toxins, however, is also important 
for the treatment of antibiotic-sensitive bacteria, as antibiotic-mediated 
killing of the bacteria may result in a massive release of toxins that 
results in deterioration of the clinical condition of the patient.
METhODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METhODS
This study was performed with the approval of and in strict accordance with 
the UK Home Office and the University of Liverpool ethics committee (Home 
Office Project License Number 40/3602) as well as the Bezirksregierung 
Düsseldorf and the University of Duisburg-Essen ethics committee (protocol 
number Az. 84-02.04.2013.A282) or the University of Cincinnati ethics com-
mittee (IACUC# 10-05-10-01). Every effort was made to minimize suffering, 
and in bacterial infection experiments, mice were humanely euthanized if they 
became lethargic. All animal experiments were carried out at the Universities 
of Liverpool, Duisburg-Essen and Cincinnati.
Reagents. Streptolysin O from S. pyogenes, α-hemolysin from S. aureus, 
tetanolysin from Clostridium tetani, phospholipase C from Clostridium perf-
ringens were from Sigma. Pneumolysin was prepared as previously described33. 
HDL (3.2 mg/ml cholesterol) was from Calbiochem. LPS from E. coli or 
P. aeruginosa was from Sigma. Deuterated sphingomyelin (16:0-d31) was from 
Avanti Polar Lipids.
Cells. The human embryonic kidney cell line (HEK 293; ATCC CRL-1573) 
was maintained as previously described34. Human umbilical vein endothelial 
cells (HUVEC) were obtained from Promocell and maintained in Promocell’s 
Endothelial Cell Growth Medium. The human acute monocytic leukemia 
cell line (THP-1; ATCC TIB-202) was maintained in RPMI 1640 medium 
containing 10% FBS, 2 mM l-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin.
Bacterial cultures and supernatants. Bacterial culture supernatants were 
prepared from S. pyogenes strains 50362, 31009 (clinical isolates from blood 
culture), 30979 (clinical isolate from tissue biopsy), 31116 (clinical isolate 
from nasopharynx) and DSM 11728; S. aureus strains MRSA 2040, MRSA 
3208.21 (clinical isolate from nasopharynx), MRSA 3108.46 (clinical isolate 
from a wound) and a methicillin-sensitive S. aureus strain isolated from a 
septic patient (septic S. aureus strain) as well as from S. pneumoniae (clinical 
isolate, 111.46). The septic S. aureus strain, also used for in vivo experiments, 
produced enterotoxin D and was tested negative for Panton-Valentin- 
leukocidin (PVL) and toxic shock syndrome toxin (TSST).
The bacteria were grown overnight on blood agar plates, resuspended at 
an OD of 0.225 in 40 ml tryptic soy broth (TSB) and allowed to grow at 37 °C 
with shaking at 125 r.p.m. to an OD600 = 0.6–0.8. Bacterial cultures were cen-
trifuged at 2,800 r.p.m. for 10 min at room temperature. Culture supernatants 
were harvested and stored at −70 °C.
Liposomes. Cholesterol, sphingomyelin from egg yolk, phosphatidylcho-
line from egg yolk and phospatidylserine (sodium salt) from bovine brain 
were from Sigma. The lipids were individually dissolved in chloroform at 
1 mg/ml concentrations. For the preparation of liposomes the chloroform solu-
tions of the individual lipids were mixed in the composition and the propor-
tions, which are given in the text. Chloroform was completely evaporated for 
30 min at 60 °C, followed by 2 h under vacuum. Tyrode’s buffer (140 mM NaCl, 
5 mM KCl, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES; pH = 7.4) containing 
2.5 mM CaCl2 was added to the films of dried lipids. Following incubation 
for 30 min at 45 °C in an Eppendorf thermomixer with vigorous shaking, the 
liposomes were sonicated three times for 5 s at 6 °C in a Bandelin Sonopuls 
sonicator at 80% power. The liposomal preparations were left for at least 1 h 
at 6 °C before they were used in experiments.
Alternatively, unilamellar cholesterol:sphingomyelin (66 mol/% cholesterol; 
mean diameter = 130 nm) and sphingomyelin (100%; mean diameter = 90 nm) 
liposomes, produced according to a good manufacturing practice (GMP)-
compliant process protocol, were provided by Lascco (Geneva, Switzerland – 
product name CAL02). The amounts of liposomes are given as the amount of 
total lipids used for their preparation.
Toxin-induced cell lysis and protective effects of liposomes in vitro. The 
effects of purified toxins or bacterial culture supernatants on the prolifera-
tion of a human monocyte cell line (THP-1) were assessed in the presence or 
absence of liposomes of various lipid compositions. Routinely, 100–200 µl of a 
purified toxin solution or a bacterial culture supernatant (Ca2+-Tyrode’s buffer 
or bacterial culture broth were used as controls) were added to 100 µl (5 × 104 
cells/ml or 5 × 105 cells/ml) of cells pre-mixed with 50 µl of liposomes. After 
incubation for 3 h, 2 ml of cell culture medium was added to the tubes. The 
cells were counted for 5–14 d. The toxins and the liposomes were present for 
the whole duration of an experiment.
In human embryonic kidney epithelial cells (HEK 293) and in human 
umbilical vein endothelial cells (HUVEC), toxin-induced lysis was monitored 
as a decline of cytoplasmic fluorescence due to an efflux of intracellular GFP 
(green-fluorescent protein) or YFP (yellow-fluorescent protein). GFP or YFP 
were transiently expressed as described34. GFP- or YFP-expressing cells were 
used for laser scanning module (LSM) imaging experiments 2 d after trans-
fection. Cells, seeded on 15 mm glass coverslips (5 × 105 cells per coverslip), 
were mounted in a perfusion chamber at 25 °C in 200 µl of Tyrode’s buffer 
containing 2.5 mM CaCl2, and their fluorescence was recorded in an Axiovert 
200 M microscope with a laser scanning module LSM 510 META (Zeiss) using 
a × 63 oil immersion lens. At time-point 0, the buffer was replaced by 100 µl 
of solution containing liposomes, followed (with 20–30 s of handling delay) 
by 100 µl of the toxin-containing solution. The images were analyzed using 
the “Physiology evaluation” software package (Zeiss).
Pneumolysin binding to Ch:Sm liposomes. Pneumolysin was diluted in 
Ca2+-Tyrode’s buffer and centrifuged at 100,000g for 1 h to remove aggre-
gated protein.
In a direct binding assay, 200 ng of pneumolysin was incubated with 0–9 µg 
of cholesterol:sphingomyelin liposomes (66 mol/% cholesterol) for 20 min 
at 20 °C. Liposomes were pelleted by centrifugation at 100,000g for 2 h. 
pneumolysin content in the pellets and in the supernatants was assessed by 
western blot analysis.
In a competition binding assay, 100 ng of pneumolysin was incubated 
with or without THP-1 cells (5 × 105 cells/ml) and with or without 100 µg of 
cholesterol:sphingomyelin liposomes (66 mol/% cholesterol) for 20 min at 20 °C. 
The samples were centrifuged at 134 g; supernatants were collected and fur-
ther centrifuged at 100,000g for 2 h. Low-speed and high-speed pellets were 
dissolved in 50 µl of SDS-PAGE sample buffer. The protein of the high-speed 
supernatants was precipitated by 10% trichloroacetic acid in the presence of 
1 mg/ml bovine serum albumin, pelleted and dissolved in 50 µl of SDS-PAGE 
sample buffer. Pneumolysin content in the samples was assessed by western 
blot analysis. Monoclonal antibody against pneumolysin (1F11; Santa Cruz 
Biotechnology) was used at 1:500 dilution.
Release of CXCL8 was measured in culture supernatants of HUVEC cells 
24 h after treatment with 15 ng (30 ng/ml) of pneumolysin in the presence or 
absence of 40 µg/ml cholesterol:sphingomyelin (66 mol/% cholesterol) lipo-
somes by Bioplex assay according to the manufacturer’s instructions.
Protective effects of liposomes in vivo. 6- to 8-week-old, age matched, 
C57BL6/J male mice were used for S. aureus in vivo infection experiments. All 
experiments undertaken were approved by local authorities. S. aureus were 
grown overnight on blood agar plates, the bacteria were resuspended at an OD 
of 0.225 in 40 ml TSB and allowed to grow at 37 °C with shaking at 125 r.p.m. 
to the early logarithmic phase for 1 h. Bacterial cultures were then pelleted 
by centrifugation at 2,800g r.p.m. and washed in phosphate buffered saline. 
3 × 106 CFU bacteria were resuspended in 100 µl of 0.9% saline and injected 
intravenously into mice. A 1:1 mixture of cholesterol:sphingomyelin (66 mol/% 
cholesterol) and sphingomyelin-only liposomes was injected at the indicated 
times and doses in 0.9% saline. Controls received saline only. Survival was 
determined over 7 d.
6- to 8-week-old, age matched, MF1 (Charles River, UK) female mice were 
used for S. pneumoniae infection experiments. Bacterial inoculum for infection 
was prepared from stocks frozen in mid-log phase. Aliquots were thawed, cen-
trifuged (13,000g, 2 min) and washed with endotoxin-free PBS before infec-
tion. For induction of pneumococcal pneumonia, mice were anesthetized with 
a mixture of O2 and isofluorane and infected intranasally with 1 × 106 CFU 
S. pneumoniae serotype 2 (strain D39) in PBS. Liposome preparations were 
administered intranasally 30 min after infection. For induction of bacteremia, 
1 × 106 CFU D39 were injected into the tail vein. Liposome preparations were 
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administered intravenously at the indicated times and doses. Tail bleeds were 
done 24 h after infection to assess bacteremia.
In all experiments mice were monitored for signs of disease using 
the scheme of Morton35 and were euthanized once disease had reached the 
“lethargic” state.
Biodistribution of liposomes. Cholesterol:sphingomyelin (66 mol/% choles-
terol) and sphingomyelin-only liposomes, each containing 6% of deuterated 
sphingomyelin were prepared as described above. Healthy mice and mice that 
were intravenously infected with S. aureus were injected with 100 mg/kg of the 
deuterated liposomes. Mice were euthanized immediately, 6.5 h or 24 h after 
liposomal injection (n = 4 for each time point). Blood, lungs, kidneys, aortas, 
livers, intestines and spleens were removed and analyzed by mass spectrometry. 
16:0-d31 sphingomyelin was extracted and quantified as recently described36. 
Sample analysis was carried out by rapid resolution liquid chromatography-
MS/MS using a Q-TOF 6530 mass spectrometer (Agilent Technologies) operat-
ing in the positive electrospray ionization mode. Chromatographic separation 
on the Zobrax Eclipse column (C8, 2.1 × 150 mm, 3.5 µm particle size; Agilent 
Technologies) was achieved by gradient elution using mobile-phase A (water/
formic acid 100:0.1 v/v) and mobile-phase B (acetonitrile/methanol/formic 
acid 50:50:0.1 v/v). The precursor ions of 12:0 sphingomyelin (m/z 647.5123) 
as internal standard and 16:0-d31 sphingomyelin (m/z 734.7619) were cleaved 
into the fragment ion of m/z 184.3. Quantification was performed with Mass 
Hunter Software (Agilent Technologies).
Antibiotic treatment. In the pneumococcal sepsis model, penicillin 
(25 mg/kg) was given intraperitoneally (i.p.) at 10 and 24 h after infection. 
In the staphylococcal sepsis model, vancomycin (100 mg/kg) was given i.p. at 
1 and 9 h after infection.
Injection of bacterial supernatants. S. aureus was grown overnight on blood 
agar plates. Bacteria were resuspended at an OD of 0.225 in 40 ml TSB and 
allowed to grow at 37 °C with shaking at 125 r.p.m. to the early logarithmic 
phase for 1 h. Bacteria were centrifuged at 3,200 r.p.m., the supernatant col-
lected, centrifuged again, a 150 µl aliquot of the supernatant collected and 
incubated for 4 h with 100 mg/kg liposomes consisting of a 1:1 mixture of 
cholesterol:sphingomyelin (66 mol/% cholesterol) and sphingomyelin-only 
liposomes at 37 °C. Controls were supplemented with the same volume PBS. 
After the 4 h incubation, samples were centrifuged at 20,000g and 150 µl of 
supernatant was injected into mice i.v.
Liposomal treatment of LPS-septic mice. LPS from E. coli or P. aeruginosa 
was injected i.p. 45 min before intravenous application of liposomes.
TNF-alpha release. TNF-α was measured in lung homogenates or serum 
(diluted 1:10 in PBS) obtained from healthy mice; healthy liposome-treated 
mice; mice infected with S. pneumoniae D39; and D39-infected mice that were 
treated with the liposomes by enzyme-linked immunosorbent assay (ELISA) 
(BioLegend), according to manufacturer’s instructions.
Blood leukocytes. Blood leukocytes were counted in lung homogenates or 
serum (diluted 1:10 in PBS) by flow cytometry. Mouse tissue cell suspensions, 
at 2 × 108 cells/ml were incubated with purified anti-Fc receptor blocking 
antibody (anti-CD16/CD32) before addition of antibodies against cell surface 
markers. A combination of fluorescein isothiocyanate (FITC)-, phycoerythrin 
(PE)-, PE-Cy7- and allophycocyanin (APC)-conjugated monoclonal antibod-
ies (eBioscience) were used. CD19 was used to identify B cells, CD3, CD4 and 
CD8 to identify T cells and Gr-1 and CD11b to identify neutrophils. In each 
experiment the appropriate monoclonal control antibodies and single conju-
gate controls were included. Alternatively, blood leukocytes were quantified 
by their typical forward versus sideward scatter using flow cytometry. Samples 
were analyzed using a Becton Dickinson FACScalibur flow cytometer running 
CellQuest acquisition and analyzed using FlowJo software (Tree Star).
Lung edema in vivo after S. aureus infection. S. aureus was grown overnight 
on blood agar plates, the bacteria were resuspended at an OD of 0.225 in 40 ml 
TSB and allowed to grow at 37 °C with shaking at 125 r.p.m. to the early 
logarithmic phase for 1 h. Bacteria were centrifuged at 2,800 r.p.m., washed 
once in PBS and 5 × 106 CFU were i.v. injected in a volume of 100 µl. Controls 
were injected with PBS. We then determined survival and lung edema by 
measuring wet and dry weight as well as Evans Blue leakage 12 h after the 
infection. Liposomes (100 mg/kg; 1:1 mixture of cholesterol:sphingomyelin 
(66 mol/% cholesterol) and sphingomyelin-only liposomes) were injected 
2 and 6 h after the infection. Evans Blue (20 mg/kg) was i.v. injected, mice were 
euthanized after 10 min, the lung was flushed with PBS via the right heart, 
removed and dried for 2 d at 56 °C. The dried tissue was suspended in 0.8 ml 
formamide per 100 mg dry tissue and incubated for 24 h at 60 °C. The OD of 
the samples was then analyzed by 620 nm and the concentration determined 
using a standard curve of Evans Blue.
Killing capacity of blood samples. 40 µl of mouse blood were incubated 
with 10,000 CFU S. aureus at 37 °C for 4 h with shaking at 125 r.p.m. in 
the presence of either liposomes at 1 mg/ml (1:1 mixture of cholesterol: 
sphingomyelin (66 mol/% cholesterol) and sphingomyelin-only liposomes) or 
the same volume PBS. After the incubation, aliquots were plated on LB plates, 
grown o/n and the CFU were counted.
NO release. Blood samples were taken from healthy mice and we performed a 
Percoll density gradient centrifugation to purify neutrophils. Neutrophils were 
incubated ex vivo with 5 µM 4-amino-5-methylamino-2′,7′-difluorofluorescein 
(DAFFM) (Molecular Probes) at 37 °C for 30 min. DAFFM is nonfluorescent 
and reacts with NO to a fluorescent substrate. Samples were washed with PBS 
and then further incubated with 0.5 mg/ml of each cholesterol:sphingomyelin 
(66 mol/% cholesterol) and sphingomyelin-only liposomes (1 mg/ml total) at 
37 °C for 30 min or with the same volume of PBS. They were then challenged 
with S. aureus at an multiplicity of infection (MOI) of 1 cell per 10 bacteria 
and NO was determined over a period of 90 min in the presence or absence of 
L-NAME, an i-NOS inhibitor. Samples were then analyzed by fluorescence-
activated cell sorting (FACS). The relative NO production induced by S. aureus, 
as is indicated by the change of the fluorescence of the DAFFM, was calculated 
by using the formula ∆DAFFM mean fluorescence after S. aureus = mean fluo-
rescence after S. aureus – mean fluorescence without infection. Fluorescence 
intensity of the L-NAME group was calculated as following: ∆DAFFM mean 
fluorescence after S. aureus + L-NAME = mean fluorescence after S. aureus + 
L-NAME − mean fluorescence L-NAME only.
ROS release. Blood samples were taken from healthy mice, and we performed 
a Percoll density gradient centrifugation to obtain neutrophils. The cells were 
incubated ex vivo with 10 µM 2′,7′ dichlorodihydrofluorescein diacetate acetyl 
ester (DCF) (H2DCFDA, Molecular Probes) at 37 °C for 30 min, incubated 
with 0.5 mg/ml of each liposome (1 mg/ml total as above) at 37 °C for 30 min 
or with the same volume of PBS, challenged with S. aureus at an MOI of 1 cell 
per 10 bacteria and ROS was determined over a period of 60 min. Controls 
were incubated with 100 U/ml superoxide dismutase (SOD) and 10 U/ml cata-
lase. Samples were analyzed by FACS. The relative ROS production induced 
by S. aureus, as is indicated by the change of the fluorescence of the DCF, was 
calculated by using the formula ∆DCF mean fluorescence = mean fluorescence 
after S. aureus - mean fluorescence after [S. aureus + SOD + catalase].
Bactericidal activity of liposomes. To define the minimum bactericidal 
concentration (MBC), we followed the guidelines proposed by the Clinical 
and Laboratory Standards Institute37. For the broth microtiter dilution tests, 
96-well plates supplemented with 50 µl of 0.5–16 mg/ml liposomes were 
 inoculated with 50 µl of Mueller Hinton broth containing a bacterial cell 
suspension of 1–5 × 105 colony-forming units (CFU)/ml. The plates were 
incubated for 24 h at 36 °C. MBC was tested by transferring 10 µl aliquots 
from the wells of the broth microtiter dilution plates onto Columbia blood 
agar (Oxoid). The inoculated plates were further incubated for 24 h at 36 °C 
and then colonies were counted.
Statistical analysis, sample size planning and measures against bias. For 
the comparison of continuous variables from independent groups we used 
Student’s t-test for two groups and one-way ANOVA for more than two groups 
followed by post-hoc Student’s t-tests for all pairwise comparisons applying 
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Bonferroni correction for multiple testing. Between-group comparisons of 
survival variables was performed by log-rank test.
As sensitivity analyses, which generally supported the claim of the prespeci-
fied analyses, we applied Welch’s t-tests and exact Wilcoxon-Mann-Whitney 
tests for continuous variables and the latter also for survival variables given 
that no censoring events happened during the follow-up. Furthermore, to 
follow our sample size plan, we also applied Fisher’s exact test to compare the 
survival rates at the last observation between groups. All reported P values are 
two-sided and corrected for comparison-wise multiplicity.
The sample size planning of the mouse experiments with outcome death 
was based on two-sided Fisher’s exact tests (i.e., a comparison of event rates as 
suggested by Shah38) even though the pre-planned analyses was for survival 
times. When aiming to detect a between-group difference in survival rates 
between 15% and 90% (at the last follow-up, assuming no censoring events 
before), ten animals per group (1:1 allocation) are required for a comparison-
wise power of 90% at a significance level α = 5% (two-sided); for n = 8/n = 12 
per group the power will be about 87%/98%. The sample size planning for the 
continuous variables in, for example, the S. aureus in vivo infection experi-
ments, was based on two-sided Wilcoxon-Mann-Whitney tests (software: 
G*Power Version 3.1.7 of the University of Duesseldorf, Germany). When 
aiming at detecting a large standardized effect of 2.5 (in units of a s.d. of a 
standard normal distribution) between means of two groups, four animals 
per group (1:1 allocations) are required for a comparison-wise power of 80% 
at a significance level α = 5% (two-sided). Thus, the animal experiments were 
powered to detect large effects.
Mice were divided into cages of equal size (usually three to five mice) on 
arrival by animal unit technical staff with no involvement in study design. 
Thus, for a single experiment, all mice used were of the same age and sex and 
were within 2 g weight of each other. Cages were numbered and the numbers 
randomly assigned to an experimental treatment group. The investigators 
were not blinded to the group allocation during the experiment and/or when 
assessing the outcome.
For the pain score, mice were scored separately by two independent 
researchers and one animal unit technical staff member with no involvement 
in study design and recorded.
Investigators were blinded for histology and Evans Blue experiments.
33. McNeela, E.A. et al. Pneumolysin activates the NLRP3 inflammasome and promotes 
proinflammatory cytokines independently of TLR4. PLoS Pathog. 6, e1001191 
(2010).
34. Babiychuk, E.B., Monastyrskaya, K., Potez, S. & Draeger, A. Intracellular Ca(2+) 
operates a switch between repair and lysis of streptolysin O-perforated cells. 
Cell Death Differ. 16, 1126–1134 (2009).
35. Morton, D.B. Pain and laboratory animals. Nature 317, 106 (1985).
36. Merrill, A.H. Jr., Sullards, M.C., Allegood, J.C., Kelly, S. & Wang, E. Sphingolipidomics: 
high-throughput, structure-specific, and quantitative analysis of sphingolipids by 
liquid chromatography tandem mass spectrometry. Methods 36, 207–224 
(2005).
37. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial 
susceptibility tests for bacteria that grow aerobically – Twenty second information 
supplement: Approved standard M07–A8. (CLSI, Wayne, PA, USA, 2009).
38. Shah, H. How to calculate sample size in animal studies. Natl. J. Physiol. Pharm. 
Pharmacol. 1, 35–39 (2011).
